These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 28945636

  • 1. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S.
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [Abstract] [Full Text] [Related]

  • 2. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S.
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [Abstract] [Full Text] [Related]

  • 3. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.
    Scand J Gastroenterol; 2015 Jan; 50(9):1110-7. PubMed ID: 25865965
    [Abstract] [Full Text] [Related]

  • 4. Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A.
    Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
    [Abstract] [Full Text] [Related]

  • 5. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
    Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A.
    World J Gastroenterol; 2019 May 21; 25(19):2354-2364. PubMed ID: 31148906
    [Abstract] [Full Text] [Related]

  • 6. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T, Frymoyer A, Christofferson M, Yu H, Bass D, Park KT.
    Inflamm Bowel Dis; 2018 Jan 18; 24(2):227-234. PubMed ID: 29361094
    [Abstract] [Full Text] [Related]

  • 7. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H.
    World J Gastroenterol; 2022 Jun 21; 28(23):2582-2596. PubMed ID: 35949356
    [Abstract] [Full Text] [Related]

  • 8. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B, Iborra M, Sáez-González E, Marqués-Miñana MR, Moret I, Cerrillo E, Tortosa L, Bastida G, Hinojosa J, Poveda-Andrés JL, Nos P.
    Dig Dis; 2019 Jun 21; 37(2):108-115. PubMed ID: 30149385
    [Abstract] [Full Text] [Related]

  • 9. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
    Frin AC, Filippi J, Boschetti G, Flourie B, Drai J, Ferrari P, Hebuterne X, Nancey S.
    Dig Liver Dis; 2017 Jan 21; 49(1):11-16. PubMed ID: 27693318
    [Abstract] [Full Text] [Related]

  • 10. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S.
    Inflamm Bowel Dis; 2015 Feb 21; 21(2):331-6. PubMed ID: 25625487
    [Abstract] [Full Text] [Related]

  • 11. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb 21; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 12. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M, Duricova D, Bortlik M, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Lukas M.
    Dig Dis; 2017 Feb 21; 35(1-2):91-100. PubMed ID: 28147356
    [Abstract] [Full Text] [Related]

  • 13. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M, Nikolac Gabaj N, Ćelap I, Grazio S, Tomašić V, Bišćanin A, Mitrović J, Đerek L, Morović-Vergles J, Vrkić N, Štefanović M.
    Rheumatol Int; 2021 Dec 21; 41(12):2195-2203. PubMed ID: 34623480
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Ferreira AI, Lima Capela T, Arieira C, Xavier S, Cotter J.
    Eur J Gastroenterol Hepatol; 2024 Nov 01; 36(11):1314-1318. PubMed ID: 39166409
    [Abstract] [Full Text] [Related]

  • 15. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.
    J Gastroenterol; 2014 Apr 01; 49(4):674-82. PubMed ID: 23666424
    [Abstract] [Full Text] [Related]

  • 16. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
    Nemoz B, Ternant D, Bailly S, Gautier-Veyret E, Jourdil JF, Bonaz B, Stanke-Labesque F.
    Br J Clin Pharmacol; 2019 Apr 01; 85(4):722-728. PubMed ID: 30575085
    [Abstract] [Full Text] [Related]

  • 17. Serum infliximab concentrations in pediatric inflammatory bowel disease.
    Hämäläinen A, Sipponen T, Kolho KL.
    Scand J Gastroenterol; 2013 Jan 01; 48(1):35-41. PubMed ID: 23148710
    [Abstract] [Full Text] [Related]

  • 18. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
    Pavlidis P, Gulati S, Dubois P, Chung-Faye G, Sherwood R, Bjarnason I, Hayee B.
    Scand J Gastroenterol; 2016 Dec 01; 51(12):1447-1452. PubMed ID: 27400728
    [Abstract] [Full Text] [Related]

  • 19. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S, Cheifetz A, Fabien N, Barrau M, Paul S.
    J Crohns Colitis; 2024 May 31; 18(5):679-685. PubMed ID: 37934041
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X.
    Inflamm Bowel Dis; 2013 Nov 31; 19(12):2568-76. PubMed ID: 24013361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.